Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Hyperthermia ; 32(6): 595-9, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-27269515

RESUMEN

BACKGROUND: Isolated limb perfusion (ILP) is an established and effective treatment for advanced melanoma and soft tissue sarcomas of the extremities with a high overall response rate. The aim of this study was to describe our experience of ILP for more rare types of tumours. METHODS: Patients with Merkel cell carcinoma (MCC) (n = 4), squamous cell carcinoma (SCC) (n = 2), B-cell lymphoma (n = 1), desmoid tumours (n = 3), pigmented villonodular synovitis (PVNS) (n = 1) and giant cell tumour (n = 1) were treated with ILP and analysed retrospectively. RESULTS: The four patients with in-transit MCC had three complete responses (CR) and one partial response (PR); the two patients with SCC had one CR and one stable disease (SD); the patients with desmoid tumours had two PR and one SD. A CR was also observed for the patient with a giant cell tumour, but the patient with PVNS had a SD. The patient with cutaneous metastases of B-cell lymphoma showed a CR, however with rapid systemic progression. Local toxicity according to Wieberdink was grade II in 10 patients (83%) and grade III in two patients (17%). CONCLUSIONS: These results show that ILP can be used as a treatment option also for more rare disease entities when other treatments have failed.


Asunto(s)
Quimioterapia del Cáncer por Perfusión Regional , Hipertermia Inducida , Neoplasias Abdominales/tratamiento farmacológico , Neoplasias Abdominales/terapia , Poliposis Adenomatosa del Colon/tratamiento farmacológico , Poliposis Adenomatosa del Colon/terapia , Antineoplásicos Alquilantes/uso terapéutico , Carcinoma de Células de Merkel/tratamiento farmacológico , Carcinoma de Células de Merkel/terapia , Carcinoma de Células Escamosas/tratamiento farmacológico , Carcinoma de Células Escamosas/terapia , Extremidades , Fibromatosis Agresiva/tratamiento farmacológico , Fibromatosis Agresiva/terapia , Tumores de Células Gigantes/tratamiento farmacológico , Tumores de Células Gigantes/terapia , Humanos , Linfoma de Células B/tratamiento farmacológico , Linfoma de Células B/terapia , Melfalán/uso terapéutico , Perfusión , Enfermedades Raras/tratamiento farmacológico , Enfermedades Raras/terapia , Sinovitis Pigmentada Vellonodular/tratamiento farmacológico , Sinovitis Pigmentada Vellonodular/terapia , Factor de Necrosis Tumoral alfa/uso terapéutico
2.
Head Neck ; 34(3): 454-7, 2012 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-22311466

RESUMEN

BACKGROUND: Oncogenic osteomalacia is a rare paraneoplastic syndrome characterized by osteomalacia, which occurs as a result of excess renal phosphate excretion caused by fibroblast growth factor-23 secreted by mesenchymal tumors. This entity is rare in head and neck cancers. We report a rare case of oncogenic osteomalacia in a patient with an anterior skull base giant cell tumor. METHODS AND RESULTS: A 34-year-old woman presented with a 5-year history of progressive weakness in both lower limbs and the trunk. Hypophosphatemia and hypocalcemia had been noted by a local physician, but her symptoms persisted despite receiving calcium and vitamin D supplements. A recent onset of epistaxis and nasal blockage led to referral to the head and neck services. Nasal endoscopy revealed a left nasal cavity mass. Further evaluation with imaging studies revealed a mass in the nasal cavity with intracranial extension. Biopsy of the lesion suggested a neurogenic tumor. A putative diagnosis of anterior skull base neurogenic tumor with paraneoplastic hypophosphatemia was made. After the biochemical parameters were corrected, the patient underwent craniofacial resection. The final histopathologic study suggested the lesion as a "giant cell tumor." During the postoperative period the patient's biochemical and clinical symptoms improved dramatically, allowing her to regain normal mobility. CONCLUSIONS: Clinicians and pathologists must be aware of the clinical symptoms, laboratory abnormalities, and pathologic features of oncogenic osteomalacia, which may be caused by tumors in the head and neck and thus make an exhaustive effort to diagnose the same.


Asunto(s)
Tumores de Células Gigantes/complicaciones , Cavidad Nasal , Neoplasias de Tejido Conjuntivo/diagnóstico , Neoplasias de Tejido Conjuntivo/etiología , Neoplasias Nasales/complicaciones , Adulto , Femenino , Tumores de Células Gigantes/diagnóstico , Tumores de Células Gigantes/terapia , Humanos , Neoplasias de Tejido Conjuntivo/terapia , Neoplasias Nasales/diagnóstico , Neoplasias Nasales/terapia , Osteomalacia , Síndromes Paraneoplásicos
3.
Chir Narzadow Ruchu Ortop Pol ; 59(1): 59-63, 1994.
Artículo en Polaco | MEDLINE | ID: mdl-7555324

RESUMEN

The paper presents results of treatment of 16 patients operated on because of giant cell tumor. Frequent local recurrence after curettage makes the authors to suggest more common use of the thermal or chemical destruction of the neoplastic cells to achieve oncologic sterility.


Asunto(s)
Neoplasias Óseas/terapia , Neoplasias Femorales/terapia , Tumores de Células Gigantes/terapia , Recurrencia Local de Neoplasia/terapia , Tibia , Adolescente , Adulto , Antineoplásicos/uso terapéutico , Niño , Terapia Combinada , Femenino , Tumores de Células Gigantes/diagnóstico por imagen , Humanos , Hipertermia Inducida , Masculino , Persona de Mediana Edad , Radiografía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA